Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer
1996

Effect of Neoadjuvant Therapy on Breast Cancer

Sample size: 100 publication Evidence: moderate

Author Information

Author(s): J-C Gazet, RC Coombes, HT Ford, M Griffin, C Corbishley, V Makinde, S Lowndes, J Quilliam, R Sutcliffe

Primary Institution: Breast Research Unit, St. George's Hospital, London SWJ7, UK.

Hypothesis

Endocrine therapy might have a role in neoadjuvant therapy of breast cancer, provided that the ER status can be determined.

Conclusion

Neoadjuvant therapy based on estrogen receptor status can effectively downgrade breast cancer, increasing the opportunity for conservative surgery.

Supporting Evidence

  • 47 patients with ER-positive tumors had a 40.4% response rate to endocrine therapy.
  • 53 patients with ER-negative tumors had a 60% response rate to chemotherapy.
  • 41% of early breast cancer patients achieved complete clinical resolution after chemotherapy.

Takeaway

Doctors gave different treatments to breast cancer patients based on whether their tumors were sensitive to hormones, and this helped many patients avoid more serious surgery.

Methodology

Patients were assigned to receive either chemotherapy or endocrine therapy based on their estrogen receptor status, and their responses were assessed after 3 months.

Limitations

The sample size for some comparisons was too small to allow valid statistical assessment.

Participant Demographics

Patients aged between 30 and 69, with a mean age of 54.02.

Statistical Information

P-Value

0.001

Statistical Significance

p=0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication